RGCC Technology

Basic Methodology And Assay

The first innovation is in selecting the most appropriate sample:

It is well defined and widely accepted in the scientific community that the primary tumor consists of the stroma [fibroblasts, monocytes, lymphocytes, etc.] and the malignant cells that [are in homogeneous] as they are composed from different subgroups and subclones with different characteristics and capabilities. Only a few populations will develop metastatic ability that will allow them to invade the surrounding tissue, move to the circulation and perform the transition from epithelial to mesenchymal (EMT). These are known as Tube Circulating Cells [ CTC's] . A large proportion of CTCsare actually stem cells from cancer. These cells have all the information and capacity required for microcolonization and micrometastases and will later develop into potent micrometastases. For this reason RGCC selected blood samples as the most appropriate form for the analysis, since it includes cancer cells with relevant information both for the calculation of the risk and for the powerful metastases.

Innovation to find and isolate CTCs:

RGCC uses powerful classifiers and flow cytometers as well as negative selection based on interrogation. We are able to isolate the relevant CTCs and not enrich them so we can have a pure sample of CTCs and simultaneously collect the entire group of CTCs from a single blood sample.

Adequate expansion of CTCs:

The CTCs will expand as the "cancer stem cell" as the cell and then enter an exponential phase of growth, which will generate a respectful number of circulating stem cells (CSCs) in a short period of time. While managing to keep both the genotype and the cell phenotype intact, they prevent any change in primary circulating stem cells. Thus, following the final expansion we will have maintained the identical genotype.

Chemosensitivity / chemoresistance cerification in viability assays:

The information obtained from the analysis of the gene expression will be validated in a micro culture where the effect of each indicated substance will be tested. These tests overcome the problem of linearity between gene expression and levels of protein expression.

Gene-expressive Profile of CSCs:

The expanded cells will be analyzed for an expressive profile of a microarray analysis of the genome. So now we have all the information on the epigenetic screening of CSCs. This profile will tell us which therapies the CSCs will be sensitive or resistant to.

Information Extracted From The Document
(Basic Methodology And Assay) On The Rgcc Website